Edit

Aimmune

https://www.aimmune.com/

Last activity: 30.01.2026

Active

Categories: BioTechDrugEdTechFoodTechHealthTechMedTechNonprofitProductResearchScience

Aimmune is located in Brisbane, California - the heart of San Francisco’s biotechnology hub - with additional offices in Durham, North Carolina; the Paddington area of London, England; Dublin, Ireland; and Munich, Germany.

Likes

289

Followers

1.59K

Mentions

Location: United States, California, Brisbane

Employees: 201-500

Phone: +1 650-614-5220

Total raised: $145M

Founded date: 2011

Twitter

Facebook

Investors 6

Date	Name	Website
-	SWK Holdin...	swkhold.co...
-	Aisling Ca...	aislingcap...
-	Foresite C...	foresiteca...
-	RA Capital...	racap.com
-	Vivo Capit...	vivocapita...
-	Longitude ...	longitudec...

Funding Rounds 1

Date	Series	Amount	Investors
04.11.2016	-	$145M	-

Mentions in press and media 20

Date	Title	Description
30.01.2026	PharmNovo enhances its Board ahead of Phase II development	PharmNovo enhances its Board ahead of Phase II development Fri, Jan 30, 2026 08:04 CET Report this content PharmNovo AB announces changes to its Board of Directors, welcoming two new members as the company prepares for its next phase of cli...
13.02.2025	FreeOx Biotech Celebrates Landmark 2024 with Record Growth: New Hires, Groundbreaking Trial Selections, and Major Funding Milestones	FreeOx Biotech Innovative Biotech Company Expands Executive Team with Three C-Suite Appointments and Advances Pipeline with Key Trial Evaluations BARCELONA and PALO ALTO, Feb. 13, 2025 /PRNewswire-PRWeb/ -- FreeOx Biotech, a clinical-stage ...
06.06.2024	Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023	Transaction ensures Nestlé Health Science will continue to commercialize the product BRIDGEWATER, N.J., June 6, 2024 /PRNewswire/ -- Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of ...
03.03.2022	Egg allergy trials halted by Aimmune; Atlas closes its 13th fund for $450M	A Phase II trial for Aimmune’s drug to treat children and young adults with egg allergies has been terminated. “The study was prematurely terminated by the Sponsor based on difficulties in meeting enrollment goals, especially during the COV...
23.09.2020	Healthcare VC Firm Longitude Capital Closes $585M Fund	What You Should Know: – Healthcare venture capital firm Longitude Capital announces the close of its $585M Longitude Venture Partners IV, L.P. (“LVP4”) fund to invest in transformative healthcare companies. – LVP4 will invest opportunistica...
23.09.2020	Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies	- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date, Longitude portfolio companies announced 4 IP...
31.08.2020	Aimmune Therapeutics soars 172% after Nestle agrees to acquire the peanut allergy treatment company for $2.6 billion	Aimmune Therapeutics soared 172% on Monday after Nestle Health Science agreed to acquire the company for $34.50 per share, or $2.6 billion. Aimmune developed a treatment for peanut allergies, Palforzia, which was approved by the FDA in Janu...
05.02.2020	Nestlé puts $200M more behind a treatment for peanut allergy	Aimmune’s patients won’t ever be able to eat much or even most of their candy, but every time they open a capsule, they’ll be consuming a product Nestlé helped produce. Since the immunotherapy company completed its Phase II s...
13.09.2019	FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug	A panel of experts convened by the Food and Drug Administration voted in support of the agency approving a drug to treat patients with peanut allergy. The FDA’s Allergenic Products Advisory Committee voted 7-2 Friday that available efficacy...
20.06.2019	Assessing the value of new food allergy treatments must include quality of life	Walk into any classroom in America today and you’ll likely find at least two children with a food allergy. More than 40% of such children have experienced a serious allergic reaction such as anaphylaxis, a severe, potentially life-threateni...
12.11.2018	Nestlé ups its bet on Aimmune’s peanut allergy drug to $276M as NDA filing looms, rivalry intensifies	Nestlé Health Science is upping its bet on Aimmune Therapeutics by $98 million $AIMT, with its now $276 million stake in the company giving it 19% of the biotech’s equity. Allied on Aimmune’s peanut allergy med, Nestlé is b...
05.05.2018	A life sciences firm run by a top VC and a cofounder of Alphabet’s life sciences arm, just raised its biggest fund yet	There’s no end to the number of fascinating devices and therapies being created right now in the fields of health and life sciences. The investors behind them are often pretty interesting, too, given the expertise needed to make informed be...
22.02.2018	Evelo Bio raises $47.5M for I/O work; Vertex gets started on a fast pivotal effort for triple CF combo	→ Seven months after Google-backed Evelo Biosciences brought its total venture raise to $100 million, the microbial experts are at it again. Evelo has raised another $47.5 million, according to a new filing with the SEC. Flag...
04.11.2016	Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics	BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy), an approach to treating life-threatening food allergies, today anno...
29.06.2016	The biotech IPO feast flags as investors lose their appetite for R&D risk	There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund...
07.06.2016	Longitude Capital raises $525M for third fund spanning early to late stage medtech investments	The investment firm expects to invest an average of $15 million to 25 million per investment in approximately 25 companies. It raised $385 million for its second fund in 2012. Galletti highlighted some of the technologies in which it has de...
08.07.2015	Morning Read: Novartis gets green light from FDA for heart failure drug, CVS bows out of Chamber of Commerce over tobacco	“We were surprised to read recent press reports concerning the U.S. Chamber of Commerce’s position on tobacco products outside the United States…CVS Health’s purpose is to help people on their path to better health, and we fundamentally bel...
-	Morning Read: Novartis gets green light from FDA for heart failure drug, CVS bows out of Chamber of Commerce over tobacco	TOP STORIES The FDA has green-lighted Novartis’ heart failure drug Entresto six weeks ahead of schedule. Heart failure is a common condition affecting 5.1 million people in the U.S. alone and up to 50 percent of patients die within five yea...
-	FDA expert panel gives thumbs-up to Aimmune’s peanut allergy drug	A panel of experts convened by the Food and Drug Administration voted in support of the agency approving a drug to treat patients with peanut allergy. The FDA’s Allergenic Products Advisory Committee voted 7-2 Friday that available efficacy...
-	Longitude Capital raises $525M for third fund spanning early to late stage medtech investments	Longitude Capital, a life science investment firm targeting mostly mid to late stage companies with about one quarter for early stage businesses, has made its first close for Longitude Venture Partners III, raising a total of $525 million, ...

Aimmune

Investors 6

Funding Rounds 1

Mentions in press and media 20

Reviews 0